NK细胞疗法-话题@MedSci

#NK细胞疗法#

10篇内容 | 753人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1573372, encodeId=8dff15e3372bb, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, objectTitle=基因工程NK细胞疗法获FDA快速通道资格，联合单抗治疗晚期胃癌, objectType=article, longId=294423, objectId=dfa02944232c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfa02944232c, replyNumber=0, likeNumber=37, createdTime=2022-01-22, rootId=0, userName=feather83, userId=7e9715863942, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfa02944232c, moduleTitle=基因工程NK细胞疗法获FDA快速通道资格，联合单抗治疗晚期胃癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfa02944232c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573371, encodeId=fb7415e33711f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, objectTitle=Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法, objectType=article, longId=206408, objectId=55db20640853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55db20640853, replyNumber=0, likeNumber=23, createdTime=2021-01-31, rootId=0, userName=feather83, userId=7e9715863942, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55db20640853, moduleTitle=Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55db20640853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573370, encodeId=b16515e33706f, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, objectTitle=Oncternal Therapeutics与卡罗林斯卡研究所合作开发靶向ROR1的CAR-T和CAR-NK细胞疗法, objectType=article, longId=205517, objectId=6a4020551e01, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a4020551e01, replyNumber=0, likeNumber=41, createdTime=2021-01-10, rootId=0, userName=feather83, userId=7e9715863942, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a4020551e01, moduleTitle=Oncternal Therapeutics与卡罗林斯卡研究所合作开发靶向ROR1的CAR-T和CAR-NK细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a4020551e01)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573369, encodeId=c8f315e336985, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, objectTitle=赛诺菲3.58亿美元收购Kiadis，获得NK细胞疗法, objectType=article, longId=203007, objectId=725620300e3c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=725620300e3c, replyNumber=0, likeNumber=31, createdTime=2020-11-08, rootId=0, userName=feather83, userId=7e9715863942, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=725620300e3c, moduleTitle=赛诺菲3.58亿美元收购Kiadis，获得NK细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=725620300e3c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573368, encodeId=160515e336872, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, objectTitle=通用型NK细胞疗法初创公司，宣布获得7800万美元的A轮融资, objectType=article, longId=196575, objectId=4cf61965e5c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cf61965e5c2, replyNumber=0, likeNumber=36, createdTime=2020-06-28, rootId=0, userName=feather83, userId=7e9715863942, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cf61965e5c2, moduleTitle=通用型NK细胞疗法初创公司，宣布获得7800万美元的A轮融资, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cf61965e5c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573367, encodeId=0de215e336782, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, objectTitle=AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据, objectType=article, longId=196313, objectId=dbde196313ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbde196313ba, replyNumber=0, likeNumber=42, createdTime=2020-06-25, rootId=0, userName=feather83, userId=7e9715863942, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbde196313ba, moduleTitle=AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbde196313ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573366, encodeId=957b15e3366c7, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, objectTitle=NEJM：CAR-NK细胞疗法用于CD19阳性淋巴瘤, objectType=article, longId=187581, objectId=5c3c18e5811a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c3c18e5811a, replyNumber=0, likeNumber=27, createdTime=2020-02-08, rootId=0, userName=feather83, userId=7e9715863942, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c3c18e5811a, moduleTitle=NEJM：CAR-NK细胞疗法用于CD19阳性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c3c18e5811a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573365, encodeId=978c15e3365af, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, objectTitle=NantKwest的NK细胞疗法联合T细胞激活剂在转移性胰腺癌患者的早期临床试验中，将肿瘤根除, objectType=article, longId=186458, objectId=5e3118645817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e3118645817, replyNumber=0, likeNumber=36, createdTime=2020-01-19, rootId=0, userName=feather83, userId=7e9715863942, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e3118645817, moduleTitle=NantKwest的NK细胞疗法联合T细胞激活剂在转移性胰腺癌患者的早期临床试验中，将肿瘤根除, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e3118645817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573364, encodeId=6b4215e3364c8, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, objectTitle=FDA批准NKMax America的NK细胞疗法SNK01用于难治性癌症患者的1期临床试验, objectType=article, longId=161784, objectId=176a161e8475, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=176a161e8475, replyNumber=0, likeNumber=36, createdTime=2019-03-08, rootId=0, userName=feather83, userId=7e9715863942, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=176a161e8475, moduleTitle=FDA批准NKMax America的NK细胞疗法SNK01用于难治性癌症患者的1期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=176a161e8475)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573363, encodeId=9d2f15e3363b5, content=<a href='/topic/show?id=93a11285330' target=_blank style='color:#2F92EE;'>#NK细胞疗法#</a>, objectTitle=默沙东达成6.95亿美元合作，豪赌NK细胞疗法, objectType=article, longId=150498, objectId=367b150498a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367b150498a4, replyNumber=0, likeNumber=36, createdTime=2018-10-08, rootId=0, userName=feather83, userId=7e9715863942, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367b150498a4, moduleTitle=默沙东达成6.95亿美元合作，豪赌NK细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=367b150498a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

NK细胞疗法

2020-05-29

feather83 (审核中...)

前往app查看评论内容

#NK细胞疗法#

基因工程NK细胞疗法获FDA快速通道资格，联合单抗治疗晚期胃癌

2022-01-22

feather83 (审核中...)

前往app查看评论内容

#NK细胞疗法#

Artiva Biotherapeutics宣布与默克公司达成**全球合作和许可协议，以开发候选CAR-NK细胞疗法

2021-01-31

feather83 (审核中...)

前往app查看评论内容

#NK细胞疗法#

Oncternal Therapeutics与卡罗林斯卡研究所合作开发靶向ROR1的CAR-T和CAR-NK细胞疗法

2021-01-10

feather83 (审核中...)

前往app查看评论内容

#NK细胞疗法#

赛诺菲3.58亿美元收购Kiadis，获得NK细胞疗法

2020-11-08

feather83 (审核中...)

前往app查看评论内容

#NK细胞疗法#

通用型NK细胞疗法初创公司，宣布获得7800万美元的A轮融资

2020-06-28

feather83 (审核中...)

前往app查看评论内容

#NK细胞疗法#

AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据

2020-06-25

feather83 (审核中...)

前往app查看评论内容

#NK细胞疗法#

NEJM：CAR-NK细胞疗法用于CD19阳性淋巴瘤

2020-02-08

feather83 (审核中...)

前往app查看评论内容

#NK细胞疗法#

NantKwest的NK细胞疗法联合T细胞激活剂在转移性胰腺癌患者的早期临床试验中，将肿瘤根除

2020-01-19

feather83 (审核中...)

前往app查看评论内容

#NK细胞疗法#

FDA批准NKMax America的NK细胞疗法SNK01用于难治性癌症患者的1期临床试验

2019-03-08

feather83 (审核中...)

前往app查看评论内容

#NK细胞疗法#

默沙东达成6.95亿美元合作，豪赌NK细胞疗法

2018-10-08

科室
- - 订阅+
  - 更多科室
工具
服务